Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Corcept Therapeutics (CORT) Debt to Equity: 2016-2017

Historic Debt to Equity for Corcept Therapeutics (CORT) over the last 1 years, with Jun 2017 value amounting to $0.07.

  • Corcept Therapeutics' Debt to Equity fell 92.05% to $0.07 in Q2 2017 from the same period last year, while for Jun 2017 it was $0.07, marking a year-over-year decrease of 92.05%. This contributed to the annual value of $0.35 for FY2016, which is N/A change from last year.
  • Latest data reveals that Corcept Therapeutics reported Debt to Equity of $0.07 as of Q2 2017, which was down 66.09% from $0.20 recorded in Q1 2017.
  • In the past 5 years, Corcept Therapeutics' Debt to Equity ranged from a high of $1.24 in Q1 2016 and a low of $0.07 during Q2 2017.
  • Moreover, its 2-year median value for Debt to Equity was $0.48 (2016), whereas its average is $0.56.
  • Data for Corcept Therapeutics' Debt to Equity shows a maximum YoY tumbled of 92.05% (in 2017) over the last 5 years.
  • Quarterly analysis of 2 years shows Corcept Therapeutics' Debt to Equity stood at $0.35 in 2016, then slumped by 92.05% to $0.07 in 2017.
  • Its last three reported values are $0.07 in Q2 2017, $0.20 for Q1 2017, and $0.35 during Q4 2016.